eli lilly retatrutide clinical trials Phase 3 obesity trial results 2026 Lilly's triple agonist, retatrutide, delivered

A Quick Refresher on Retatrutide Retatrutide is a synthetic triple-agonist peptide that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon

"The math of insulin versus GLP-1 is pretty clear to a rational economic actor," Andrews said

The shift in revenue sources is dramatic GLP-1 drugs now constitute a majority of Lillys growth

State participation in the Medicaid Drug Rebate Program requires coverage of nearly all FDA-approved drugs for medically accepted indications, but weight-loss drugs are included in a small group of drugs that can be excluded from coverage

Many insurance companies require BMI documentation, weight history, medical necessity documentation, prior authorization, and evidence of previous weight loss attempts

Beyond delivery, the clinical challenge in MASH remains the quality of the metabolic response: safeguarding transcriptional pathways (Nrf2/NFkB) and hepatocellular integrity during weight loss